Loading…

Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII

FVIII is synthesized as a single chain precursor of approximately 280 kD with the domain structure of A1-A2-B-A3-C1-C2 and it circulates as a series of metal ion-linked heterodimers that result from cleavages at B-A3 junction as well as additional cleavages within B domain. Factor VIII is converted...

Full description

Saved in:
Bibliographic Details
Published in:Experimental & molecular medicine 1999-06, Vol.31 (2), p.95-100
Main Authors: Oh, S H, Lee, M Y, Song, D W
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c322t-55166fa5da6dea56a0830537d686164e318aee3fd7dec873f4741bef1b8aac23
cites
container_end_page 100
container_issue 2
container_start_page 95
container_title Experimental & molecular medicine
container_volume 31
creator Oh, S H
Lee, M Y
Song, D W
description FVIII is synthesized as a single chain precursor of approximately 280 kD with the domain structure of A1-A2-B-A3-C1-C2 and it circulates as a series of metal ion-linked heterodimers that result from cleavages at B-A3 junction as well as additional cleavages within B domain. Factor VIII is converted to its active form, factor VIIIa, upon proteolytic cleavages by thrombin and is a heterotrimer composed of the A1, A2, and A3-C1-C2 subunits. A1 subunits of factor VIIIa terminates with 36 residue segment (Met337-Arg372) rich in acidic residues. This segment is removed after cleavages at Arg336 by activated protein C, which results in inactivation of the cofactor. In the present study, site-directed mutagenesis of FVIII at Arg336 to Gln336 was performed in order to produce an inactivation resistant mutant rFVIII (rFVIIIm) with an extended physiological stability. A recombinant mutant heavy chain of FVIII (rFVIII-Hm; Arg336 to Gln336) and wild-type light chain of FVIII (rFVIII-L) were expressed in Baculovirus-insect cell (Sf9) system, and a biologically active recombinant mutant FVIII (rFVIIIm) was reconstituted from rFVIII-Hm and rFVIII-L in the FVIII-depleted human plasma containing 40 mM CaCl2. The rFVIIIm exhibited cofactor activity of FVIIIa (2.85 x 10(-2) units/mg protein) that sustained the high level activity during in vitro incubation at 37 degrees C for 24 h, while the cofactor activity of normal plasma was declined steadily for the period. These results indicate that rFVIIIm (Arg336 to Gln336) expressed in Baculovirus-insect cell system is inactivation resistant in the plasma coagulation milieu and may be useful for the treatment of hemophilia A.
doi_str_mv 10.1038/emm.1999.16
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1038_emm_1999_16</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10410309</sourcerecordid><originalsourceid>FETCH-LOGICAL-c322t-55166fa5da6dea56a0830537d686164e318aee3fd7dec873f4741bef1b8aac23</originalsourceid><addsrcrecordid>eNpNkE1Lw0AQhhdRbK2evMseFUndj2STHKVYDRQ8WLyGyX40K0m2ZLeF3vrTTVoPnoYZ3veBeRC6p2ROCc9edNvOaZ7ncyou0JSRnEUipvwSTSljIuKC8gm68f6HEJbEaXyNJpTEQ5XkU3T8OnSh1t567AzutXRtZTvoAq4a5xSWDja7BoJ1HTYgg-vxd1EU-HE5jidca9gfMHQKN3ZTByxrsJ0_HUZY54MNu1N7wA99u9fYuL4d1xPiFl0ZaLy--5sztF6-rRcf0erzvVi8riLJGQtRklAhDCQKhNKQCCAZJwlPlcgEFbHmNAOtuVGp0jJLuRkepZU2tMoAJOMz9HzGyt5532tTbnvbQn8oKSlHjeWgsRw1llQM6YdzerurWq3-Zc_e-C8NtG7_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII</title><source>Full-Text Journals in Chemistry (Open access)</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Oh, S H ; Lee, M Y ; Song, D W</creator><creatorcontrib>Oh, S H ; Lee, M Y ; Song, D W</creatorcontrib><description>FVIII is synthesized as a single chain precursor of approximately 280 kD with the domain structure of A1-A2-B-A3-C1-C2 and it circulates as a series of metal ion-linked heterodimers that result from cleavages at B-A3 junction as well as additional cleavages within B domain. Factor VIII is converted to its active form, factor VIIIa, upon proteolytic cleavages by thrombin and is a heterotrimer composed of the A1, A2, and A3-C1-C2 subunits. A1 subunits of factor VIIIa terminates with 36 residue segment (Met337-Arg372) rich in acidic residues. This segment is removed after cleavages at Arg336 by activated protein C, which results in inactivation of the cofactor. In the present study, site-directed mutagenesis of FVIII at Arg336 to Gln336 was performed in order to produce an inactivation resistant mutant rFVIII (rFVIIIm) with an extended physiological stability. A recombinant mutant heavy chain of FVIII (rFVIII-Hm; Arg336 to Gln336) and wild-type light chain of FVIII (rFVIII-L) were expressed in Baculovirus-insect cell (Sf9) system, and a biologically active recombinant mutant FVIII (rFVIIIm) was reconstituted from rFVIII-Hm and rFVIII-L in the FVIII-depleted human plasma containing 40 mM CaCl2. The rFVIIIm exhibited cofactor activity of FVIIIa (2.85 x 10(-2) units/mg protein) that sustained the high level activity during in vitro incubation at 37 degrees C for 24 h, while the cofactor activity of normal plasma was declined steadily for the period. These results indicate that rFVIIIm (Arg336 to Gln336) expressed in Baculovirus-insect cell system is inactivation resistant in the plasma coagulation milieu and may be useful for the treatment of hemophilia A.</description><identifier>ISSN: 1226-3613</identifier><identifier>ISSN: 2092-6413</identifier><identifier>EISSN: 2092-6413</identifier><identifier>DOI: 10.1038/emm.1999.16</identifier><identifier>PMID: 10410309</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Baculoviridae - genetics ; Blotting, Western ; Cell Line ; Factor VIII - biosynthesis ; Factor VIII - chemistry ; Factor VIII - genetics ; Factor VIII - metabolism ; Genetic Vectors ; Humans ; Mutagenesis, Site-Directed ; Recombinant Proteins - biosynthesis ; Recombinant Proteins - chemistry ; Recombinant Proteins - genetics ; Recombinant Proteins - metabolism ; Spodoptera</subject><ispartof>Experimental &amp; molecular medicine, 1999-06, Vol.31 (2), p.95-100</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c322t-55166fa5da6dea56a0830537d686164e318aee3fd7dec873f4741bef1b8aac23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10410309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oh, S H</creatorcontrib><creatorcontrib>Lee, M Y</creatorcontrib><creatorcontrib>Song, D W</creatorcontrib><title>Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII</title><title>Experimental &amp; molecular medicine</title><addtitle>Exp Mol Med</addtitle><description>FVIII is synthesized as a single chain precursor of approximately 280 kD with the domain structure of A1-A2-B-A3-C1-C2 and it circulates as a series of metal ion-linked heterodimers that result from cleavages at B-A3 junction as well as additional cleavages within B domain. Factor VIII is converted to its active form, factor VIIIa, upon proteolytic cleavages by thrombin and is a heterotrimer composed of the A1, A2, and A3-C1-C2 subunits. A1 subunits of factor VIIIa terminates with 36 residue segment (Met337-Arg372) rich in acidic residues. This segment is removed after cleavages at Arg336 by activated protein C, which results in inactivation of the cofactor. In the present study, site-directed mutagenesis of FVIII at Arg336 to Gln336 was performed in order to produce an inactivation resistant mutant rFVIII (rFVIIIm) with an extended physiological stability. A recombinant mutant heavy chain of FVIII (rFVIII-Hm; Arg336 to Gln336) and wild-type light chain of FVIII (rFVIII-L) were expressed in Baculovirus-insect cell (Sf9) system, and a biologically active recombinant mutant FVIII (rFVIIIm) was reconstituted from rFVIII-Hm and rFVIII-L in the FVIII-depleted human plasma containing 40 mM CaCl2. The rFVIIIm exhibited cofactor activity of FVIIIa (2.85 x 10(-2) units/mg protein) that sustained the high level activity during in vitro incubation at 37 degrees C for 24 h, while the cofactor activity of normal plasma was declined steadily for the period. These results indicate that rFVIIIm (Arg336 to Gln336) expressed in Baculovirus-insect cell system is inactivation resistant in the plasma coagulation milieu and may be useful for the treatment of hemophilia A.</description><subject>Animals</subject><subject>Baculoviridae - genetics</subject><subject>Blotting, Western</subject><subject>Cell Line</subject><subject>Factor VIII - biosynthesis</subject><subject>Factor VIII - chemistry</subject><subject>Factor VIII - genetics</subject><subject>Factor VIII - metabolism</subject><subject>Genetic Vectors</subject><subject>Humans</subject><subject>Mutagenesis, Site-Directed</subject><subject>Recombinant Proteins - biosynthesis</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - genetics</subject><subject>Recombinant Proteins - metabolism</subject><subject>Spodoptera</subject><issn>1226-3613</issn><issn>2092-6413</issn><issn>2092-6413</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNpNkE1Lw0AQhhdRbK2evMseFUndj2STHKVYDRQ8WLyGyX40K0m2ZLeF3vrTTVoPnoYZ3veBeRC6p2ROCc9edNvOaZ7ncyou0JSRnEUipvwSTSljIuKC8gm68f6HEJbEaXyNJpTEQ5XkU3T8OnSh1t567AzutXRtZTvoAq4a5xSWDja7BoJ1HTYgg-vxd1EU-HE5jidca9gfMHQKN3ZTByxrsJ0_HUZY54MNu1N7wA99u9fYuL4d1xPiFl0ZaLy--5sztF6-rRcf0erzvVi8riLJGQtRklAhDCQKhNKQCCAZJwlPlcgEFbHmNAOtuVGp0jJLuRkepZU2tMoAJOMz9HzGyt5532tTbnvbQn8oKSlHjeWgsRw1llQM6YdzerurWq3-Zc_e-C8NtG7_</recordid><startdate>19990630</startdate><enddate>19990630</enddate><creator>Oh, S H</creator><creator>Lee, M Y</creator><creator>Song, D W</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19990630</creationdate><title>Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII</title><author>Oh, S H ; Lee, M Y ; Song, D W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c322t-55166fa5da6dea56a0830537d686164e318aee3fd7dec873f4741bef1b8aac23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Baculoviridae - genetics</topic><topic>Blotting, Western</topic><topic>Cell Line</topic><topic>Factor VIII - biosynthesis</topic><topic>Factor VIII - chemistry</topic><topic>Factor VIII - genetics</topic><topic>Factor VIII - metabolism</topic><topic>Genetic Vectors</topic><topic>Humans</topic><topic>Mutagenesis, Site-Directed</topic><topic>Recombinant Proteins - biosynthesis</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - genetics</topic><topic>Recombinant Proteins - metabolism</topic><topic>Spodoptera</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oh, S H</creatorcontrib><creatorcontrib>Lee, M Y</creatorcontrib><creatorcontrib>Song, D W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Experimental &amp; molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oh, S H</au><au>Lee, M Y</au><au>Song, D W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII</atitle><jtitle>Experimental &amp; molecular medicine</jtitle><addtitle>Exp Mol Med</addtitle><date>1999-06-30</date><risdate>1999</risdate><volume>31</volume><issue>2</issue><spage>95</spage><epage>100</epage><pages>95-100</pages><issn>1226-3613</issn><issn>2092-6413</issn><eissn>2092-6413</eissn><abstract>FVIII is synthesized as a single chain precursor of approximately 280 kD with the domain structure of A1-A2-B-A3-C1-C2 and it circulates as a series of metal ion-linked heterodimers that result from cleavages at B-A3 junction as well as additional cleavages within B domain. Factor VIII is converted to its active form, factor VIIIa, upon proteolytic cleavages by thrombin and is a heterotrimer composed of the A1, A2, and A3-C1-C2 subunits. A1 subunits of factor VIIIa terminates with 36 residue segment (Met337-Arg372) rich in acidic residues. This segment is removed after cleavages at Arg336 by activated protein C, which results in inactivation of the cofactor. In the present study, site-directed mutagenesis of FVIII at Arg336 to Gln336 was performed in order to produce an inactivation resistant mutant rFVIII (rFVIIIm) with an extended physiological stability. A recombinant mutant heavy chain of FVIII (rFVIII-Hm; Arg336 to Gln336) and wild-type light chain of FVIII (rFVIII-L) were expressed in Baculovirus-insect cell (Sf9) system, and a biologically active recombinant mutant FVIII (rFVIIIm) was reconstituted from rFVIII-Hm and rFVIII-L in the FVIII-depleted human plasma containing 40 mM CaCl2. The rFVIIIm exhibited cofactor activity of FVIIIa (2.85 x 10(-2) units/mg protein) that sustained the high level activity during in vitro incubation at 37 degrees C for 24 h, while the cofactor activity of normal plasma was declined steadily for the period. These results indicate that rFVIIIm (Arg336 to Gln336) expressed in Baculovirus-insect cell system is inactivation resistant in the plasma coagulation milieu and may be useful for the treatment of hemophilia A.</abstract><cop>United States</cop><pmid>10410309</pmid><doi>10.1038/emm.1999.16</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1226-3613
ispartof Experimental & molecular medicine, 1999-06, Vol.31 (2), p.95-100
issn 1226-3613
2092-6413
2092-6413
language eng
recordid cdi_crossref_primary_10_1038_emm_1999_16
source Full-Text Journals in Chemistry (Open access); Springer Nature - nature.com Journals - Fully Open Access
subjects Animals
Baculoviridae - genetics
Blotting, Western
Cell Line
Factor VIII - biosynthesis
Factor VIII - chemistry
Factor VIII - genetics
Factor VIII - metabolism
Genetic Vectors
Humans
Mutagenesis, Site-Directed
Recombinant Proteins - biosynthesis
Recombinant Proteins - chemistry
Recombinant Proteins - genetics
Recombinant Proteins - metabolism
Spodoptera
title Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIII
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A01%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20of%20recombinant%20blood%20coagulation%20factor%20VIII%20(FVIII)%20heavy%20and%20light%20chains%20and%20reconstitution%20of%20active%20form%20of%20FVIII&rft.jtitle=Experimental%20&%20molecular%20medicine&rft.au=Oh,%20S%20H&rft.date=1999-06-30&rft.volume=31&rft.issue=2&rft.spage=95&rft.epage=100&rft.pages=95-100&rft.issn=1226-3613&rft.eissn=2092-6413&rft_id=info:doi/10.1038/emm.1999.16&rft_dat=%3Cpubmed_cross%3E10410309%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c322t-55166fa5da6dea56a0830537d686164e318aee3fd7dec873f4741bef1b8aac23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/10410309&rfr_iscdi=true